Advanced or metastatic gastrointestinal stromal tumors: Systemic treatment options

Journal of Surgical Oncology

Volumn 104, Issue 8, 2011, Pages 888-895

  Caram, Megan V ^a   Schuetze, Scott M ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

GIST; imatinib; sunitinib

Indexed keywords

CISPLATIN; DACARBAZINE; DOXORUBICIN; FUROSEMIDE; IMATINIB; MITOMYCIN C; PLATELET DERIVED GROWTH FACTOR RECEPTOR; SUNITINIB;

ABDOMINAL PAIN; ACUTE GRANULOCYTIC LEUKEMIA; ADVANCED CANCER; ANEMIA; ARTICLE; CANCER GROWTH; CHEMOEMBOLIZATION; CONGESTIVE HEART FAILURE; DIARRHEA; DISEASE COURSE; DRUG DOSE COMPARISON; DRUG METABOLISM; DRUG USE; FATIGUE; FLUID RETENTION; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; METASTASIS; MOLECULARLY TARGETED THERAPY; MUSCLE CRAMP; NAUSEA; NEUTROPENIA; ONCOGENE C KIT; PERICARDIAL EFFUSION; PLEURA EFFUSION; PRIORITY JOURNAL; PROTEIN FUNCTION; RASH; SIDE EFFECT; SKIN DISCOLORATION;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; INDOLES; NEOPLASM METASTASIS; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; PYRROLES;

EID: 80855156582     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21930     Document Type: Article

References (46)

1. Demetri GD, von Mehren M, Antonescu CR, et al.: NCCN Task Force report: Update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw 2010; 8: S1-S41.
2. Nilsson B, Bumming P, Meis-Kindblom JM, et al.: Gastrointestinal stromal tumors: The incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era-A population-based study in western Sweden. Cancer 2005; 103: 821-829. (Pubitemid 40216412)
3. Blanke CD, Demetri GD, von Mehren M, et al.: Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008; 26: 620-625. (Pubitemid 351264357)
4. Reith JD, Goldblum JR, Lyles RH, et al.: Extragastrointestinal (soft tissue) stromal tumors: An analysis of 48 cases with emphasis on histologic predictors of outcome. Mod Pathol 2000; 13: 577-585. (Pubitemid 30332111)
5. Miettinen M, Sobin LH, Lasota J,: Gastrointestinal stromal tumors of the stomach: A clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol 2005; 29: 52-68. (Pubitemid 40023952)
6. DeMatteo RP, Lewis JJ, Leung D, et al.: Two hundred gastrointestinal stromal tumors: Recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231: 51-58. (Pubitemid 30043939)
7. Heinrich MC, Corless CL, Demetri GD, et al.: Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003; 21: 4342-4349. (Pubitemid 46621810)
8. Hirota S, Ohashi A, Nishida T, et al.: Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology 2003; 125: 660-667. (Pubitemid 37070684)
9. Pantaleo MA, Astolfi A, Di Battista M, et al.: Insulin-like growth factor 1 receptor expression in wild-type GISTs: A potential novel therapeutic target. Int J Cancer 2009; 125: 2991-2994.
10. Braconi C, Bracci R, Bearzi I, et al.: Insulin-like growth factor (IGF) 1 and 2 help to predict disease outcome in GIST patients. Ann Oncol 2008; 19: 1293-1298. (Pubitemid 351911960)
11. Andersson J, Sihto H, Meis-Kindblom JM, et al.: NF1-associated gastrointestinal stromal tumors have unique clinical, phenotypic, and genotypic characteristics. Am J Surg Pathol 2005; 29: 1170-1176. (Pubitemid 41232989)
12. Miettinen M, Fetsch JF, Sobin LH, et al.: Gastrointestinal stromal tumors in patients with neurofibromatosis 1: A clinicopathologic and molecular genetic study of 45 cases. Am J Surg Pathol 2006; 30: 90-96. (Pubitemid 43740214)
13. Agarwal R, Robson M,: Inherited predisposition to gastrointestinal stromal tumor. Hematol Oncol Clin North Am 2009; 23: 1-13.
14. Gold JS, Gonen M, Gutierrez A, et al.: Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: A retrospective analysis. Lancet Oncol 2009; 10: 1045-1052.
15. Edmonson JH, Marks RS, Buckner JC, et al.: Contrast of response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas. Cancer Invest 2002; 20: 605-612. (Pubitemid 37210030)
16. Dematteo RP, Heinrich MC, El-Rifai WM, et al.: Clinical management of gastrointestinal stromal tumors: Before and after STI-571. Hum Pathol 2002; 33: 466-477. (Pubitemid 34747865)
17. Berthet B, Sugarbaker TA, Chang D, et al.: Quantitative methodologies for selection of patients with recurrent abdominopelvic sarcoma for treatment. Eur J Cancer 1999; 35: 413-419. (Pubitemid 29151938)
18. Eilber FC, Rosen G, Forscher C, et al.: Surgical resection and intraperitoneal chemotherapy for recurrent abdominal sarcomas. Ann Surg Oncol 1999; 6: 645-650.
19. Hirota S, Isozaki K, Moriyama Y, et al.: Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279: 577-580. (Pubitemid 28067289)
20. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al.: Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001; 344: 1052-1056. (Pubitemid 32267975)
21. Verweij J, Casali PG, Zalcberg J, et al.: Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: Randomised trial. Lancet 2004; 364: 1127-1134. (Pubitemid 39296599)
22. Blanke CD, Rankin C, Demetri GD, et al.: Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 2008; 26: 626-632. (Pubitemid 351264358)
23. Zalcberg JR, Verweij J, Casali PG, et al.: Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer 2005; 41: 1751-1757. (Pubitemid 41132637)
24. Eisenberg BL, Harris J, Blanke CD, et al.: Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): Early results of RTOG 0132/ACRIN 6665. J Surg Oncol 2009; 99: 42-47.
25. McAuliffe JC, Hunt KK, Lazar AJ, et al.: A randomized, phase II study of preoperative plus postoperative imatinib in GIST: Evidence of rapid radiographic response and temporal induction of tumor cell apoptosis. Ann Surg Oncol 2009; 16: 910-919.
26. Andtbacka RH, Ng CS, Scaife CL, et al.: Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol 2007; 14: 14-24. (Pubitemid 44954266)
27. Hohenberger P, Oladeji O, Licht T, et al.: Neoadjuvant imatinib and organ preservation in locally advanced gastrointestinal stromal tumors (GIST. J Clin Oncol 2009; 27: 548s (abstract 10550).
28. Hecker A, Hecker B, Bassaly B, et al.: Dramatic regression and bleeding of a duodenal GIST during preoperative imatinib therapy: Case report and review. World J Surg Oncol 2010; 8: 47.
29. Saied GM, Kensarah AM,: Six months neoadjuvant imatinib improves resectability potential of gastric stromal tumors in Egyptian patients. Int J Surg 2010; 8: 105-108.
30. Demetri GD, Wang Y, Wehrle E, et al.: Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. J Clin Oncol 2009; 27: 3141-3147.
31. Blay JV, Le Cesne A, Ray-Coquard I, et al.: Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: The French Sarcoma Group. J Clin Oncol 2007; 25: 1107-1113. (Pubitemid 46596763)
32. Le Cesne A, Ray-Coquard I, Bui BN, et al.: Continuous versus interruption of imatinib in responding patients with advanced GIST after three years of treatment: A prospective randomized phase III trial of the French Sarcoma Group. J Clin Oncol 2007; 25: 546s (abstract 10005).
33. Guilhot F,: Indications for imatinib mesylate therapy and clinical management. Oncologist 2004; 9: 271-281. (Pubitemid 38756876)
34. Ganjoo KN, Demetri GD, Jacobs C, et al.: Acute myeloid leukemia in patients with gastrointestinal stromal tumors treated with Gleevec. Leuk Lymphoma 2009; 50: 1882-1884.
35. Kerkela R, Grazette L, Yacobi R, et al.: Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006; 12: 908-916. (Pubitemid 44175142)
36. Debiec-Rychter M, Sciot R, Le Cesne A, et al.: KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006; 42: 1093-1103. (Pubitemid 44275331)
37. Heinrich MC, Owzar K, Corless CL, et al.: Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol 2008; 26: 5360-5367.
38. Heinrich MC, Maki RG, Corless CL, et al.: Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol 2008; 26: 5352-5359.
39. Debiec-Rychter M, Dumez H, Judson I, et al.: Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2004; 40: 689-695. (Pubitemid 38326618)
40. Corless CL, Schroeder A, Griffith D, et al.: PDGFRA mutations in gastrointestinal stromal tumors: Frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol 2005; 23: 5357-5364. (Pubitemid 46206989)
41. Maleddu A, Pantaleo MA, Nannini M, et al.: Mechanisms of secondary resistance to tyrosine kinase inhibitors in gastrointestinal stromal tumours (Review). Oncol Rep 2009; 21: 1359-1366.
42. Demetri GD, van Oosterom AT, Garrett CR, et al.: Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet 2006; 368: 1329-1338. (Pubitemid 44528723)
43. George S, Blay JY, Casali PG, et al.: Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer 2009; 45: 1959-1968.
44. Zhu X, Stergiopoulos K,: Wu S: Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: Systematic review and meta-analysis. Acta Oncol 2009; 48: 9-17.
45. Chu TF, Rupnick MA, Kerkela R, et al.: Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007; 370: 2011-2019. (Pubitemid 350236338)
46. Desai J, Yassa L, Marqusee E, et al.: Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med 2006; 145: 660-664. (Pubitemid 46768841)